Elanco Animal Health Incorporated logo

Elanco Animal Health Incorporated

ELAN

NYSEHealthcareDrug Manufacturers - Specialty & Generic

Previous close

$23.97

+$0.41 · +1.74%

Aug 21, 4:00 PM ET

Pre-market

$24.36

+$0.39 · +1.63%

Aug 24, 8:51 AM ET

ELAN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

35

Expensive

Momentum

52

Neutral

Sentiment

57

Mixed

Risk resilience

59

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Jeffrey N. Simmons
Listed since
Sep 20, 2018
Employees
9,650

Market position

Day range

Current $23.97

52-week range

Current $23.97

Open
$23.91
Previous close
$23.56
Volume
4.75M
0.76× average
Average volume
6.3M
Average daily volume
Market cap
11.97B USD
Beta
1.69
Market reference 1
50-day average
$24.5388
-2.32% below average
200-day average
$23.6075
+1.54% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
14.71B USD
P/E (TTM)
-58.46×
P/B (TTM)
1.82×
P/S (TTM)
2.38×
EV / EBITDA
21.75×
Earnings yield
-2.07%
Free cash flow yield
2.53%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
52.59%
Operating margin
9.20%
Net margin
-3.96%
Return on equity
-3.54%
Return on assets
-1.74%
Return on invested capital
2.13%

Financial health

Debt / equity
0.59×
Current ratio
2.17×
Altman Z-score
1.38
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends52%23%-6%-35%Gross margin, FY2021: 43.58%Gross margin, FY2022: 44.66%Gross margin, FY2023: 43.88%Gross margin, FY2024: 43.01%Gross margin, FY2025: 43.48%Operating margin, FY2021: 6.38%Operating margin, FY2022: 8.71%Operating margin, FY2023: 7.38%Operating margin, FY2024: 5.65%Operating margin, FY2025: 5.34%Net margin, FY2021: -10.14%Net margin, FY2022: -1.77%Net margin, FY2023: -27.87%Net margin, FY2024: 7.61%Net margin, FY2025: -4.92%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 43.58%. Gross margin FY2022 44.66%. Gross margin FY2023 43.88%. Gross margin FY2024 43.01%. Gross margin FY2025 43.48%. Operating margin FY2021 6.38%. Operating margin FY2022 8.71%. Operating margin FY2023 7.38%. Operating margin FY2024 5.65%. Operating margin FY2025 5.34%. Net margin FY2021 -10.14%. Net margin FY2022 -1.77%. Net margin FY2023 -27.87%. Net margin FY2024 7.61%. Net margin FY2025 -4.92%.

Income trends

Revenue

4.72B USD+6.22%

Operating income

252M USD+0.40%

Net income

−232M USD−570M USD
Income trends across reported periods5.36B USD2.97B USD567.5M USD−1.83B USDRevenue, FY2021: 4.76B USDRevenue, FY2022: 4.41B USDRevenue, FY2023: 4.42B USDRevenue, FY2024: 4.44B USDRevenue, FY2025: 4.72B USDOperating income, FY2021: 304M USDOperating income, FY2022: 384M USDOperating income, FY2023: 326M USDOperating income, FY2024: 251M USDOperating income, FY2025: 252M USDNet income, FY2021: −483M USDNet income, FY2022: −78M USDNet income, FY2023: −1.23B USDNet income, FY2024: 338M USDNet income, FY2025: −232M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.76B USD. Revenue FY2022 4.41B USD. Revenue FY2023 4.42B USD. Revenue FY2024 4.44B USD. Revenue FY2025 4.72B USD. Operating income FY2021 304M USD. Operating income FY2022 384M USD. Operating income FY2023 326M USD. Operating income FY2024 251M USD. Operating income FY2025 252M USD. Net income FY2021 −483M USD. Net income FY2022 −78M USD. Net income FY2023 −1.23B USD. Net income FY2024 338M USD. Net income FY2025 −232M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue4.72B USD4.44B USD4.42B USD4.41B USD4.76B USD
Cost of goods sold2.67B USD2.53B USD2.48B USD2.44B USD2.69B USD
Gross profit2.05B USD1.91B USD1.94B USD1.97B USD2.08B USD
Research and development368M USD344M USD327M USD321M USD369M USD
Selling, general, and administrative1.43B USD1.31B USD1.29B USD1.27B USD1.4B USD
Operating expenses1.8B USD1.66B USD1.61B USD1.59B USD1.77B USD
Interest income45M USD
Interest expense220M USD339M USD277M USD256M USD264M USD
Depreciation and amortization680M USD662M USD694M USD682M USD716M USD
Operating income252M USD251M USD326M USD384M USD304M USD
Net income−232M USD338M USD−1.23B USD−78M USD−483M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+16.42%
11 comparable reports
Latest EPS result
0.34
Estimate 0.27 · Beat by 26.30%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.440.320.210.09Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 0.14, estimate 0.16, surprise -12.50%, Miss. Q2 2025, reported May 7, 2025: actual 0.37, estimate 0.31, surprise +19.35%, Beat. Q3 2025, reported Aug 7, 2025: actual 0.26, estimate 0.2, surprise +30.00%, Beat. Q4 2025, reported Nov 5, 2025: actual 0.19, estimate 0.13, surprise +46.15%, Beat. Q1 2026, reported Feb 24, 2026: actual 0.13, estimate 0.11, surprise +18.18%, Beat. Q2 2026, reported May 6, 2026: actual 0.4, estimate 0.346, surprise +15.74%, Beat. Q3 2026, reported Aug 5, 2026: actual 0.34, estimate 0.269, surprise +26.30%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.2, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.43B1.27B1.12B965.16MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 1.02B USD, estimate 1.21B USD, surprise -15.70%, Miss. Q2 2025, reported May 7, 2025: actual 1.19B USD, estimate 1.18B USD, surprise +1.28%, Beat. Q3 2025, reported Aug 7, 2025: actual 1.24B USD, estimate 1.09B USD, surprise +13.91%, Beat. Q4 2025, reported Nov 5, 2025: actual 1.14B USD, estimate 1.09B USD, surprise +4.14%, Beat. Q1 2026, reported Feb 24, 2026: actual 1.14B USD, estimate 1.09B USD, surprise +4.67%, Beat. Q2 2026, reported May 6, 2026: actual 1.37B USD, estimate 1.28B USD, surprise +7.35%, Beat. Q3 2026, reported Aug 5, 2026: actual 1.37B USD, estimate 1.31B USD, surprise +4.23%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 1.21B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$28.67

19.61% upside
Past 12 months12-month forecastHigh $30.00Average $28.67Low $26.00

Rating distribution

21 ratings
Strong buy00%
Buy1571%
Hold419%
Sell210%
Strong sell00%

Recent analyst actions

12 institutions
TD CowenmaintainBuy
CitigroupmaintainBuy

ELAN news

ELAN peers

ETFs holding ELAN

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ELAN

research.disclaimer